Skip to content

Study Details

Testing the Study Drug Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis

(IRB#: IRB_00170529)

Eosinophilic esophagitis is a disease that affects the lining of the tube between your mouth and stomach. This study will test a drug called Barzolvolimab (CDX-0159) in adults with this disease. The study wants to see if the drug will help people with the disease and is safe. People in this study will be randomly chosen to be treated with doses of Barzolvolimab (CDX-0159) and placebo. The drug and placebo are taken as a swallowed pill. A placebo is a pill that does not have the drug. Being in the study requires up to 50 weeks at the clinic. Medical tests will be done during the study to track the health of participants.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 18 years to 80 years old
  • Diagnosis and symptoms of Eosinophilic esophagitis
  • Participants of childbearing age willing to use birth control
  • Able to attend in person at a study clinic

Exclusion Criteria

  • History of other specific diseases such as Crohns
  • Severe or uncontrolled chronic diseases such as diabetes and heart disease that impact participation
  • Avoid solid foods or use a feeding tube
  • Active chronic or severe infection requiring treatment such as antibiotics
  • Prior use of Barzolvolimab (CDX-0159)

Will I be paid for my time?


For more information contact:

Amy Nichols


IRB#: IRB_00170529

PI: Kathryn Peterson


Approval Date: 2023-09-27 06:00:00

Specialties: Gastroenterology

Last Updated: 6/8/23